SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

Inicio・Lista de Acciones・Genfit

Genfit

Abierto

SectorSanidad

9.5 7.59

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.69

Máximo

9.74

Métricas clave
By Trading Economics
Ingresos	-66M -76M
Ventas	-3.6M 32M
BPA	-1.525
Margen de beneficios	-237.939
Empleados	188
EBITDA	-8M -7M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+75.44% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	53M 426M
Apertura anterior	1.91
Cierre anterior	9.5

Noticias sobre sentimiento de mercado

By Acuity

48%

52%

152 / 344 Clasificación en Healthcare

Genfit Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 jun 2026, 21:51 UTC

Principales Movimientos del Mercado

Merlin Shares Rally After Defense Department's Design Review Wraps

4 jun 2026, 23:46 UTC

Charlas de Mercado

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 jun 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 jun 2026, 23:42 UTC

Adquisiciones, fusiones, absorciones

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 jun 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

Energy Resources of Australia to Enter Trading Halt

4 jun 2026, 23:34 UTC

Charlas de Mercado

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 jun 2026, 23:08 UTC

Charlas de Mercado

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 jun 2026, 22:41 UTC

Charlas de Mercado

Australia Shares Set to Rise at the Open -- Market Talk

4 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 jun 2026, 20:44 UTC

Adquisiciones, fusiones, absorciones

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 jun 2026, 20:16 UTC

Charlas de Mercado

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 jun 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 jun 2026, 19:46 UTC

Charlas de Mercado

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 jun 2026, 19:38 UTC

Charlas de Mercado

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 jun 2026, 19:30 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 jun 2026, 18:47 UTC

Adquisiciones, fusiones, absorciones

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 jun 2026, 18:38 UTC

Ganancias

Money Quote: Tech Weakness in Context -- WSJ

4 jun 2026, 18:24 UTC

Ganancias

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 17:09 UTC

Charlas de Mercado

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 jun 2026, 16:58 UTC

Ganancias

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 16:46 UTC

Charlas de Mercado

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 jun 2026, 16:38 UTC

Ganancias

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 jun 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

4 jun 2026, 16:13 UTC

Charlas de Mercado

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 jun 2026, 16:11 UTC

Charlas de Mercado

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 jun 2026, 15:56 UTC

Charlas de Mercado

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparación entre iguales

Cambio de precio

Genfit previsión

Precio Objetivo

By TipRanks

75.44% repunte

Estimación a 12 Meses

Media 15.001 EUR 75.44%

Máximo 15 EUR

Mínimo 15 EUR

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genfit Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Genfit Dist en los últimos 3 meses.

Sentimiento

By Acuity

152 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.